आधिकारिक वित्तीय विवरणों से राजस्व, लाभ और नकदी प्रवाह का इतिहास.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
इंटरैक्टिव चार्ट और पूर्ण वित्तीय विवरण देखें → वैल्यूएशन मॉडल (DCF) →
| आय विवरण | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| कुल राजस्व | $79.7B | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B | $24.5B | $22.3B | $21.5B | $20.0B | $21.2B | $20.0B | $19.6B | $23.1B | $22.6B | $24.3B | $23.1B | $21.8B | $20.4B | $18.6B | $15.7B |
| सकल लाभ | $66.9B | $54.6B | $36.6B | $27.0B | $21.9B | $21.0B | $19.1B | $17.6B | $16.8B | $15.5B | $15.5B | $14.9B | $14.7B | $18.2B | $17.8B | $19.2B | $18.7B | $17.6B | $16.0B | $14.4B | $12.1B |
| सकल मार्जिन % | 84.0% | 83.8% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% | 74.8% | 74.9% | 78.8% | 78.8% | 79.1% | 81.1% | 80.5% | 78.5% | 77.2% | 77.4% |
| परिचालन लाभ (EBIT) | $35.0B | $29.7B | $17.5B | $10.8B | $8.7B | $7.9B | $7.2B | $6.0B | $6.0B | $4.2B | $3.9B | $3.6B | $3.3B | $5.5B | $5.0B | $6.3B | $6.8B | $6.4B | $5.5B | $4.8B | $4.1B |
| परिचालन मार्जिन % | 43.9% | 45.6% | 38.9% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% | 18.0% | 17.0% | 24.0% | 22.2% | 26.0% | 29.3% | 29.2% | 27.1% | 25.8% | 26.3% |
| शुद्ध लाभ | $26.7B | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B | $6.2B | $8.3B | $3.2B | ($204M) | $2.7B | $2.4B | $2.4B | $4.7B | $4.1B | $4.3B | $5.1B | $4.3B | ($2.1B) | $3.0B | $2.7B |
| शुद्ध मार्जिन % | 33.5% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% | 12.1% | 12.2% | 20.3% | 18.1% | 17.9% | 22.0% | 19.8% | -10.2% | 15.8% | 17.0% |
| EBITDA | $35.2B | $27.9B | $15.2B | $8.6B | $8.7B | $8.0B | $8.9B | $6.9B | $5.5B | $4.1B | $5.1B | $4.4B | $4.5B | $7.5B | $7.0B | $6.9B | $8.0B | $6.9B | $43M | $5.9B | $4.9B |
| प्रति शेयर आय (EPS) | $29.80 | $22.98 | $11.71 | $5.80 | $6.57 | $5.85 | $6.47 | $8.69 | $3.13 | $-0.19 | $2.49 | $2.18 | $2.15 | $4.19 | $3.57 | $3.90 | $4.58 | $3.94 | $-1.89 | $2.71 | $2.45 |
| बकाया शेयर (मिलियन) | 894M | 898M | 904M | 903M | 950M | 954M | 957M | 958M | 1,034M | 1,052M | 1,101M | 1,105M | 1,111M | 1,117M | 1,146M | 1,114M | 1,106M | 1,098M | 1,094M | 1,091M | 1,087M |
स्रोत: कंपनी की सार्वजनिक रिपोर्टें (SEC). किसी भी आँकड़े पर भरोसा करने से पहले SEC EDGAR पर उसकी पुष्टि करें.
बैलेंस शीट, नकदी प्रवाह, तिमाही आँकड़े और सभी वित्तीय अनुपात LLY के इंटरैक्टिव व्यूअर में उपलब्ध हैं. /companies/us/LLY
इस वेबसाइट की जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और निवेश सलाह नहीं है. कोई मूल्य लक्ष्य या सिफ़ारिश प्रकाशित नहीं की जाती.
About TickerBase · Data methodology & sources · Privacy · Terms